NEW YORK (GenomeWeb News) – PrimeraDx has landed a grant from the National Cancer Institute to develop a gene expression profiling assay that can rapidly detect diffuse large B-Cell lymphoma (DLBCL) subgroups, making it easier to diagnose the disease, select treatment options, and predict the likelihood of patient response to therapy and survival.

The company will use the $335,186 grant, funded under the Innovative Molecular Analysis Technologies Program, to develop the assay on its ICEPlex PCR-based platform, which uses formalin-fixed, paraffin-embedded specimens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.